Executive Decision: Francois Nader
In the "Executive Decision" segment, Cramer sat down with Dr. Francois Nader, president and CEO of orphan drug maker NPS Pharmaceuticals (NPSP), a stock that's up 7.7% since Cramer first got behind the company in late October.
Nader commented on his company's newly announced deal securing the rights for its Gattex drug in Europe from partner Takeda Pharmaceutical Co. for $50 million. He said the all-stock deal is a win-win for both companies and returns Gattex to NPS, which has its sole focus on orphan drugs. While the drug currently only has 72 patients, Nader said he expects between 200 to 300 patients before year's end.
Nader also commented on the price of Gattex, which costs upwards of $200,000 per year. He said that ultimately Gattex saves the system money because patients' current treatments can last for 10 to 12 hours per day and cost between $200,000 and $600,000 per patient per year.In that context, Gattex offers real value, said Nader, not to mention the fact that patients can also lead productive lives instead of living at the hospital. When asked about health insurance reimbursements for such a costly drug, Nader said reimbursements have been favorable thus far. While market conditions are different in Europe, he is not expecting major issues going forward. Cramer said he continues to like the NPS Pharmaceutical story.